5 Undervalued Pharmaceuticals Stocks for Friday, July 05
Discover the top 5 undervalued Pharmaceuticals stocks for Friday, July 05 based on AAII’s Stock Grades.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Commentary & Analysis
3 Undervalued Pharmaceuticals Stocks for Monday, May 20
Discover the top 3 undervalued Pharmaceuticals stocks for Monday, May 20 based on AAII’s Stock Grades.Grace Malone
5 Undervalued Pharmaceuticals Stocks for Tuesday, March 26
Discover the top 5 undervalued Pharmaceuticals stocks for Tuesday, March 26 based on AAII’s Stock Grades.Eunice Kim
4 Undervalued Pharmaceuticals Stocks for Friday, August 11
Discover the top 4 undervalued Pharmaceuticals stocks for Friday, August 11 based on AAII’s Stock Grades.Jack Gilleland
Is RedHill Biopharma Ltd (ADR) (RDHL) Stock a Good Investment?
Learn more about RedHill Biopharma Ltd (ADR)'s (RDHL) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Pharmaceuticals stock meets your investment needs.Cynthia McLaughlin
Financial Summary
| Share Statistics | RDHL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.7 | $608.6 | 2% |
|
| Shares Out (Mil) | na | 43.1 | na |
|
| Institutional Ownership | 68.9% | 83.7% | 42% |
|
| Float (Mil) | 5.0 | 45.1 | 12% |
|
| Beta | 5.04 | 0.73 | 99% |
|
| Avg Daily Volume (000s) | 11,157 | 309 | 97% |
|
| Price Change (52-week) |
(61.6%) | 65.2% | 12% |
|
| Growth | RDHL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (65.8%) | 6.7% | 0% |
|
| Net Income (5yr) | 65.0% | (1.5%) | 96% |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (64.9%) | (15.0%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RDHL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $317 | 1% |
|
| Net Income (TTM) (Mil) | $-0 | ($11) | 38% |
|
| EPS (TTM) | ($0.136) | ($0.700) | 35% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($6) | 22% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 17% |
|
| Enterprise Value (Q1) (Mil) | $2 | $524 | 4% |
|
| Valuation | RDHL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.73 | 2.60 | 13% |
|
| P/E | na | 17.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | RDHL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 68.8% | 96% |
|
| Net Margin | (150.0%) | 0.8% | 6% |
|
| ROA | (2.0%) | (22.5%) | 34% |
|
| ROE | 206.7% | (21.8%) | 98% |
|
| Liabilities to Assets | 83.2% | 32.8% | 77% |
|
| F-Score | 1 | 3 | na |
|
RedHill Biopharma Ltd. did not pass any screens on 9/14/2026.
